Zdravka Medarova, PhDCo-Founder and Chief Scientific Officer at TransCode TherapeuticsSpeaker
Profile
Zdravka Medarova, PhD has served as Scientific Co-Founder and a member of the advisory board of TransCode since January 2016 and is TransCode's Chief Scientific Officer. Dr. Medarova is also on the Faculty of Harvard Medical School. She has served as an Associate Professor of Radiology at Harvard Medical School since April 2016. Dr. Medarova is a geneticist/cancer biologist by training. Dr. Medarova is internationally recognized for her work on non-coding RNA for cancer therapy. She is one of the first to describe the design and application of nanoparticles as carriers of siRNA to tumors. Since then, her research has focused on developing nanotechnology and imaging tools to better understand cancer initiation and progression and applying this knowledge to design clinically relevant therapeutic and diagnostic agents against cancer.
Agenda Sessions
Phase 1 Clinical Testing of a First-in-Class ASO Therapeutic against Metastatic Cancer
, 9:15amView Session